Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. National Cancer Center, Goyang, Korea

Survival: 22.9 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: Korea
City/State/Province: Goyang
Hospital: National Cancer Center
Journal: Link
Date: 2/2012

This phase III study involved never-smokers with adenocarcinoma of the lung who had not received previous chemotherapy. Patients were separated into 2 treatment groups. Group A consisted of 159 patients with a median age of 57 years and 12% were male. Group B had 150 patients with a median age of 56.5 years and 10.7% were male.

Patients in group A were treated with the biologic therapy agent gefitinib, which works as an inhibitor of epidermal growth factor receptors (EGFR) to inhibit cell division.

Patients in group B were treated with the chemotherapy agents gemcitabine and cisplatin.

There were two treatment-related deaths due to interstitial lung disease in group A. Grade 3-4 rash and anorexia were also reported.

There was one treatment-related death due to pulmonary embolism in group B. Grade 3-4 anorexia, fatigue, and neutropenia were also reported.

The median overall survival rates for groups A and B were 22.3 and 22.9 months, respectively.

This study was partially supported by AstraZeneca, makers of Iressa (brand name for gefitinib).

Correspondence: Dr. Jin Soo Lee; email:

E-mail to a Friend Email Physician More Information